Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome

A polycystic ovary and baicalin technology, which is applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., can solve the problems of large side effects, unsatisfactory long-term effect, high recurrence rate, etc., and achieve the effect of low toxicity

Active Publication Date: 2013-09-11
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Surgical trauma is large and the long-term effect is not ideal, while the effect of drug treatment is limited, there is no positive preventive effect on the occurrence of long-term complications, and the side effects are large, it cannot be taken for a long time, and the recurrence rate is high after stopping the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome
  • Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome
  • Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] The animal model of polycystic ovary syndrome was prepared by using Wister rats, and the successful models were given drug intervention. ELISA, RT-PCR and other methods were used for detection, and statistical software SPSS16.0 was used for analysis to clarify the therapeutic effect and possible mechanism of baicalin on animal models of polycystic ovary syndrome.

[0031] 1. Materials

[0032] 1.1 Experimental animals

[0033] 190 21-day-old SPF-grade female Wister rats were provided by Shanghai Slack Experimental Animal Co., Ltd., and were bred in the Animal Center of the Sea Medicine Department of the Second Military Medical University. 25 ℃ constant temperature (50% humidity) clean-grade breeding, without feeding vitamin products, 12h light and 12h dark cycle alternately.

[0034] 1.2 Main reagents

[0035] Dehydroepiandrosterone (DHEA) was purchased from Sigma, sesame oil (for injection) was purchased from Sigma, baicalin (BAC) was purchased from Japan (TCI), spi...

Embodiment 2

[0072] NCI-H295R was selected as the model cell line for the in vitro study of polycystic ovary syndrome hyperandrogenism, and the androgen content of the cell supernatant was detected at a specific time through drug intervention at a specific concentration, and RT-PCR was used to detect the related genes. expression was identified.

[0073] 1. Materials and Methods

[0074] 1.1. Experimental cells

[0075] Due to the difficulty in obtaining clinical PCOS theca cells, and the adrenocortical carcinoma cell line (NCI-H295R) is internationally recognized as the best cell line for the study of androgen synthesis and metabolism, we chose adrenocortical carcinoma cells as experimental cells.

[0076] 1.2. Experimental reagents

[0077] Cell culture reagents DMEM / F12 medium and 0.25% trypsin were purchased from Pufei Biotech, newborn bovine serum (Nu-Serum I), ITS+PREMIX cytokines were purchased from BD Biosciences, adenylyl cyclase activator (Forskolin) was purchased from Sigma,...

Embodiment 3

[0096] Prescription: Take 2 g of baicalin, add 8 g of starch, 2 g of microcrystalline cellulose, and 0.2 g of magnesium stearate, mix well, and make tablets, capsules or granules by methods known in the art.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of baicalin in preparation of a medicine for treating polycystic ovarian syndrome. As shown in an in vivo experiment, the baicalin has obvious treatment effect on a polycystic ovarian syndrome rat model and can greatly reduce the high androgen level of the rat model, promote follicle maturity and induce ovulation; as shown in an in vitro experiment, the baicalin can inhibit the expression of androgen of a polycystic ovarian syndrome cell model. More importantly, the baicalin has small side effect and incomparable security while having no liver and kidney toxicity. Therefore, the baicalin can be used for preparing the medicine for treating polycystic ovarian syndrome and has a brilliant prospect.

Description

technical field [0001] The invention relates to a new medical application of baicalin. Background technique [0002] Scutellaria baicalensis Georgi, also known as camellia root and Tujincha root, is a plant of the Labiatae family, and its roots are used as medicine. Modern pharmacological research has found that Scutellaria baicalensis contains various flavonoids such as Wogonoside, Baicalein, and Baicalin, which have antibacterial, antiviral, anti-inflammatory, anti-allergic, anti-stress, and diuretic effects. Traditional Chinese medicine believes that Scutellaria baicalensis is bitter in taste and cold in nature, and enters the lung, heart, gallbladder, and large intestine meridian. [0003] Baicalin (Baicalin) is a flavonoid compound extracted from the root of Scutellaria baicalensis. It belongs to glucuronides. It is the most abundant active ingredient in Scutellaria baicalensis and the most pharmacologically active active ingredient in Scutellaria baicalensis. Its mole...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P15/00
Inventor 俞超芹俞瑾翟乐霞韩洁张丹英白玲玲王针织周丽虹孙帅
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com